{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-22-012326","form_type":"8-K","ticker":"NAII","cik":"0000787253","company_name":"NATURAL ALTERNATIVES INTERNATIONAL INC","filed_at":"2022-05-13T23:59:59+00:00","discovered_at":"2026-05-14T18:04:03.699688+00:00","generated_at":"2026-06-25T17:19:34.295646+00:00","sec_items":["7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"NAI Q3 net income up 30.7% to $2.5M; Q4 sales outlook +18-21%","bullets":["Q3 net sales $42.4M (-8.5% YoY); private-label manufacturing down 10.8% due to 40% drop from largest customer.","Net income $2.5M ($0.41 EPS) vs $1.9M ($0.30 EPS) YoY, up 30.7% and 36.7% respectively.","CarnoSyn royalty/license revenue rose 15.2% to $4.8M in Q3; nine-month revenue up 41.7% to $13.5M.","Q4 FY2022 guidance: net sales +18-21% YoY and operating income margin 9-12%.","Cash $18.6M, working capital $53.8M; $20M available on credit line."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-22-012326","json":"https://secwatch.observer/filing/0001437749-22-012326.json","markdown":"https://secwatch.observer/filing/0001437749-22-012326.md","text":"https://secwatch.observer/filing/0001437749-22-012326.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/787253/000143774922012326/0001437749-22-012326-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/787253/000143774922012326/naii20220512_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T17:19:34.295646+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}